杜皮卢马布在基穆拉病中迅速降低IgE和乙氨基基蛋白值:实现持续缓解
1Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Journal of investigational allergology & clinical immunology
|November 5, 2025
概括
杜皮卢马布通过减少质量体积和改善症状,有效治疗了金村病 (KD). 这种生物药物为KD患者提供了潜在的疾病修饰和类固醇节约的选择,观察到持续缓解.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
背景情况:
- 基穆拉病 (KD) 是一种罕见的慢性炎症状况,与2型免疫失调有关.
- 现有的KD治疗方法通常有效性有限.
- 针对2型细胞因子的生物药物为KD提供了一个有前途的治疗途径.
研究的目的:
- 评估dupilumab的疗效和安全性,dupilumab是一种针对IL-4和IL-13的单克隆抗体,用于治疗基穆拉病.
主要方法:
- 一个追溯的案例系列,涉及8名KD患者在一个机构接受治疗.
- 杜皮卢马布的使用遵循了阿托皮性皮炎治疗方案,根据临床反应逐渐减少剂量.
- 测量结果包括质量减少,血清IgE,乙酸蛋白计数和过敏并发症.
主要成果:
- 所有8名患者都经历了显著的质量体积减少,7人实现了完全缓解,1人实现了部分缓解.
- 观察到血清IgE水平和氨酸细胞计数显著下降.
- 没有报告任何显著的药物不良反应,并且在停药后持续缓解长达一年.
结论:
- 杜皮卢马布在治疗基穆拉病方面表现出快速和持续的疗效.
- 这些发现表明dupilumab作为一种疾病修饰和皮质类固醇节约治疗KD的潜力.
- 建议进行进一步的受控研究来证实这些结果.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
423
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
423
Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463


